CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $220.62M, lower than 95% of all stocks globally
- PositionDebt-to-equity is 0×, lower than 95% of its Biotechnology peers (median 0.07×)
- Interpretations3 currently firing — 3
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
220.62MUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
1.14xvs all stocks
52-Week Change
-72.49%vs all stocks
Market Capitalization
220.62MUSDvs all stocks (USD)
Enterprise Value
102.29MUSDvs all stocks (USD)
Forward P/E
-4.33xvs Biotechnology peers
Price to Book (MRQ)
1.96xvs Biotechnology peers
Enterprise to EBITDA
-2.22xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-9.70%vs Biotechnology peers
Return on Equity (TTM)
-12.80%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Sep 26, 2026Gross Profit (TTM)
0.00USDvs all stocks (USD)
EBITDA (TTM)
0.00USDvs all stocks (USD)
Net Income (TTM)
-13.02MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-29.29MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-27.06MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 26, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2025 · Sep 30, 2025Operating Income
-51.37MUSDvs all stocks (USD)
Pre-tax Income
-46.38MUSDFY2025 · Sep 30, 2025Net Income
-46.38MUSDFY2025 · Sep 30, 2025EBIT
-46.38MUSDFY2025 · Sep 30, 2025EBITDA (Income Statement)
-46.05MUSDFY2025 · Sep 30, 2025Research & Development
37.59MUSDFY2025 · Sep 30, 2025Selling, General & Administrative
13.82MUSDFY2025 · Sep 30, 2025Other Operating Expenses
-37.00KUSDFY2025 · Sep 30, 2025Non-operating Interest Income
4.68MUSDFY2025 · Sep 30, 2025Non-operating Interest Expense
0.00USDFY2025 · Sep 30, 2025EPS (Basic)
-0.5400USDFY2025 · Sep 30, 2025EPS (Diluted)
-0.5400USDFY2025 · Sep 30, 2025Basic Shares Outstanding
85.29MSharesFY2025 · Sep 30, 2025Diluted Shares Outstanding
85.29MSharesFY2025 · Sep 30, 2025Net Income from Continuing Operations
-46.38MUSDFY2025 · Sep 30, 2025Operating Cash Flow
-38.60MUSDFY2025 · Sep 30, 2025Cash & Cash Equivalents (End of Period)
102.58MUSDFY2025 · Sep 30, 2025Income Tax Paid
125.00KUSDFY2025 · Sep 30, 2025Starting Profit (CF Statement)
-46.38MUSDFY2025 · Sep 30, 2025Stock-based Compensation
11.55MUSDFY2025 · Sep 30, 2025Change in Accounts Receivable (CF)
1.64MUSDFY2025 · Sep 30, 2025Change in Accounts Payable (CF)
-5.38MUSDFY2025 · Sep 30, 2025Change in Other Assets/Liabilities
-37.00KUSDFY2025 · Sep 30, 2025Other Financing Charges
-2.71MUSDFY2025 · Sep 30, 2025Net Financing Cash Flow
6.49MUSDFY2025 · Sep 30, 2025Shares Outstanding
92.70MSharesUpdated Sep 26, 2026Float Shares
89.81MSharesUpdated Sep 26, 2026Shares Short
14.33MSharesUpdated Sep 26, 2026Short Ratio
19.99daysvs all stocks
Short % of Shares Outstanding
16.09%vs all stocks
% Held by Insiders
1.71%vs all stocks
% Held by Institutions
40.49%vs all stocks
Total Cash (MRQ)
118.33MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
1.28USDUpdated Sep 26, 2026Total Debt (MRQ)
0.00USDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.00xvs Biotechnology peers
Current Ratio (MRQ)
15.62xvs Biotechnology peers
Book Value per Share (MRQ)
1.21USDUpdated Sep 26, 2026Total Assets
103.81MUSDvs all stocks (USD)
Total Current Assets
103.81MUSDFY2025 · Sep 30, 2025Total Liabilities
8.95MUSDFY2025 · Sep 30, 2025Total Non-current Assets
0.00USDFY2025 · Sep 30, 2025Total Non-current Liabilities
0.00USDFY2025 · Sep 30, 2025Total Current Liabilities
8.95MUSDFY2025 · Sep 30, 2025Cash & Cash Equivalents
102.58MUSDFY2025 · Sep 30, 2025Accounts Payable
4.25MUSDFY2025 · Sep 30, 2025Deferred Revenue
805.00KUSDFY2025 · Sep 30, 2025Common Stock (Book)
87.00KUSDFY2025 · Sep 30, 2025Retained Earnings
-382.45MUSDFY2025 · Sep 30, 2025Total Shareholders' Equity
94.87MUSDvs all stocks (USD)
52-Week Low
2.25USDUpdated Sep 26, 202652-Week High
10.38USDUpdated Sep 26, 202652-Week Change
-72.49%vs all stocks
Beta
1.14xvs all stocks
50-Day MA
2.84USDUpdated Sep 26, 2026200-Day MA
3.40USDUpdated Sep 26, 2026Avg 10-Day Volume
746.91KSharesUpdated Sep 26, 2026Avg 30-Day Volume
720.52KSharesUpdated Sep 26, 2026Diluted EPS (TTM)
-0.1400USDUpdated Sep 26, 2026Other Income / Expense
316.00KUSDFY2025 · Sep 30, 20253 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Cash Elevated Relative to Current Liabilities and Total Assets
Its cash covers more of its near-term bills than in its industry, and is a large share of everything it owns.
Reads
Where is this company structurally exposed?
Decline With Range Expansion And Drawdown
The price is falling, swinging wider than usual, and sits well below its peak.
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Debt-to-equity is 0×, lower than 95% of its Biotechnology peers (median 0.07×)Notable
Debt-to-equity: 0.00Industry median: 0.07Industry P5: 0.00Peers compared: 260
Financial Health
Altman Z-Score 9.26: safe zoneNotable
Altman Z-Score: 9.26
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $220.62M, lower than 95% of all stocks globallySignificant
Market cap (USD): 220,618,483Global P5: 275,556,405.438
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 33,357,653.812
Companies that share the same coordination system — how they create, deliver, or capture value.
Eubiologics Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Samyang Biopharmaceuticals Corporation
Tier 1ProductionApproval-Gated PipelineRuleFlow
Eledon Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Koa Shoji Holdings Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Genomictree Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Keros Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Curocell Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Shanghai Shenqi Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Foghorn Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Fischer Medical Ventures Ltd
Tier 1ProductionApproval-Gated PipelineFlowRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Anbio Biotechnology Limited
3 interpretationsDecline With Range Expansion And DrawdownCash Elevated Relative to Current Liabilities and Total AssetsUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
SuperX AI Technology Limited
3 interpretationsDecline With Range Expansion And DrawdownCash Elevated Relative to Current Liabilities and Total AssetsUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Directa Plus Plc
3 interpretationsDecline With Range Expansion And DrawdownCash Elevated Relative to Current Liabilities and Total AssetsUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated